InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (3 ops.)
Discover the complete record of transactions filed by Shah Jatin, Vice-Président Exécutif. Director active across 1 companies, notably Karyopharm Therapeutics Inc.. Cumulatively, 7 filings have been logged. Total volume traded: €375k. The latest transaction was filed on 17 February 2022 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations7 total
€13,9191,306 shares@ €10.65770.0080% mcap3.6% of flow
Common Stock
SEC:0001209191-22-011650:0·
€14,6701,704 shares@ €8.60920.0084% mcap3.8% of flow
Common Stock
SEC:0001209191-22-008130:0·
€14,6701,704 shares@ €8.60920.0084% mcap7.9% of flow
Common Stock
SEC:0001209191-22-008130·
€5,453665 shares@ €8.20040.0031% mcap2.9% of flow
Common Stock
SEC:0001209191-21-046589·
€5,453665 shares@ €8.20040.0031% mcap1.4% of flow
Common Stock
SEC:0001209191-21-046589:0·
€165,71323,250 shares@ €7.12750.095% mcap89.2% of flow
Common Stock
SEC:0001209191-21-031481·
Ideal exit: 1 Feb 2022 (T+270)
€165,71323,250 shares@ €7.12750.095% mcap43.0% of flow
Common Stock
SEC:0001209191-21-031481:0·
Ideal exit: 1 Feb 2022 (T+270)
7 of 7 declarations
About Shah Jatin
Jatin Shah is the Executive Vice President and Chief Medical Officer at Karyopharm Therapeutics Inc., a biopharmaceutical company. He oversees medical and research initiatives aimed at developing new treatments for patients.
